S&P 500   4,584.46 (+0.77%)
DOW   36,128.68 (+0.21%)
QQQ   390.98 (+1.54%)
AAPL   194.33 (+1.05%)
MSFT   370.74 (+0.53%)
META   326.91 (+2.98%)
GOOGL   137.02 (+5.38%)
AMZN   146.94 (+1.67%)
TSLA   241.22 (+0.77%)
NVDA   464.34 (+2.05%)
NIO   7.48 (-3.48%)
BABA   72.28 (+1.11%)
AMD   127.78 (+9.38%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.77 (+0.88%)
CGC   0.73 (+4.13%)
GE   119.26 (-0.46%)
DIS   92.54 (+1.14%)
AMC   6.88 (+1.33%)
PFE   28.74 (-0.17%)
PYPL   58.66 (-1.46%)
XOM   98.20 (-0.92%)
S&P 500   4,584.46 (+0.77%)
DOW   36,128.68 (+0.21%)
QQQ   390.98 (+1.54%)
AAPL   194.33 (+1.05%)
MSFT   370.74 (+0.53%)
META   326.91 (+2.98%)
GOOGL   137.02 (+5.38%)
AMZN   146.94 (+1.67%)
TSLA   241.22 (+0.77%)
NVDA   464.34 (+2.05%)
NIO   7.48 (-3.48%)
BABA   72.28 (+1.11%)
AMD   127.78 (+9.38%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.77 (+0.88%)
CGC   0.73 (+4.13%)
GE   119.26 (-0.46%)
DIS   92.54 (+1.14%)
AMC   6.88 (+1.33%)
PFE   28.74 (-0.17%)
PYPL   58.66 (-1.46%)
XOM   98.20 (-0.92%)
S&P 500   4,584.46 (+0.77%)
DOW   36,128.68 (+0.21%)
QQQ   390.98 (+1.54%)
AAPL   194.33 (+1.05%)
MSFT   370.74 (+0.53%)
META   326.91 (+2.98%)
GOOGL   137.02 (+5.38%)
AMZN   146.94 (+1.67%)
TSLA   241.22 (+0.77%)
NVDA   464.34 (+2.05%)
NIO   7.48 (-3.48%)
BABA   72.28 (+1.11%)
AMD   127.78 (+9.38%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.77 (+0.88%)
CGC   0.73 (+4.13%)
GE   119.26 (-0.46%)
DIS   92.54 (+1.14%)
AMC   6.88 (+1.33%)
PFE   28.74 (-0.17%)
PYPL   58.66 (-1.46%)
XOM   98.20 (-0.92%)
S&P 500   4,584.46 (+0.77%)
DOW   36,128.68 (+0.21%)
QQQ   390.98 (+1.54%)
AAPL   194.33 (+1.05%)
MSFT   370.74 (+0.53%)
META   326.91 (+2.98%)
GOOGL   137.02 (+5.38%)
AMZN   146.94 (+1.67%)
TSLA   241.22 (+0.77%)
NVDA   464.34 (+2.05%)
NIO   7.48 (-3.48%)
BABA   72.28 (+1.11%)
AMD   127.78 (+9.38%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.77 (+0.88%)
CGC   0.73 (+4.13%)
GE   119.26 (-0.46%)
DIS   92.54 (+1.14%)
AMC   6.88 (+1.33%)
PFE   28.74 (-0.17%)
PYPL   58.66 (-1.46%)
XOM   98.20 (-0.92%)

NeuroSense Therapeutics Stock Price, News & Analysis (NASDAQ:NRSN)

$0.75
+0.03 (+3.61%)
(As of 02:32 PM ET)
Compare
Today's Range
$0.65
$0.76
50-Day Range
$0.44
$1.49
52-Week Range
$0.40
$2.91
Volume
703,028 shs
Average Volume
617,946 shs
Market Capitalization
$8.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NRSN stock logo

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSN Stock Price History

NRSN Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
NeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpoints
NeuroSense Therapeutics GAAP EPS of -$0.67
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
NeuroSense Therapeutics 9-Month Loss Narrows
NeuroSense Therapeutics to Participate in BIO-Europe Fall
NeuroSense CEO Provides Q3 2023 Update
NeuroSense Therapeutics Ltd. Wt
European Medicines Agency Grants NeuroSense SME Status
NeuroSense to Host Investor Webinar on September 12, 2023
NeuroSense CEO Provides Q2 2023 Update
See More Headlines
Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRSN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-12,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.51 per share

Miscellaneous

Free Float
N/A
Market Cap
$7.93 million
Optionable
Not Optionable
Beta
1.65
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Alon Ben-Noon (Age 44)
    Co-Founder, CEO & Director
    Comp: $619k
  • Mr. Or Eisenberg (Age 42)
    Chief Financial Officer
    Comp: $378k
  • Dr. Ferenc Tracik M.D. (Age 59)
    Chief Medical Officer
    Comp: $513k
  • Ms. Hagit Binder (Age 45)
    Chief Operation Officer
  • Dr. Niva Russek-Blum Ph.D. (Age 44)
    Chief Technology Officer
  • Ms. Yael Barak (Age 53)
    VP of Quality & Compliance
  • Ms. Keren Pushett
    Head of HR
  • Mr. Eidan Loushi
    C.R.A.














NRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroSense Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRSN shares.
View NRSN analyst ratings
or view top-rated stocks.

How have NRSN shares performed in 2023?

NeuroSense Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, NRSN stock has decreased by 42.2% and is now trading at $0.7046.
View the best growth stocks for 2023 here
.

Are investors shorting NeuroSense Therapeutics?

NeuroSense Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 234,000 shares, an increase of 89.3% from the October 31st total of 123,600 shares. Based on an average daily volume of 240,800 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.6% of the company's stock are sold short.
View NeuroSense Therapeutics' Short Interest
.

When is NeuroSense Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our NRSN earnings forecast
.

When did NeuroSense Therapeutics IPO?

(NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

Who are NeuroSense Therapeutics' major shareholders?

NeuroSense Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.05%).

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NRSN) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -